Press releases
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Brussels, Belgium – 18 August 2020 – CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners.
ENYO PHARMA ANNOUNCES MULTIPLE EYP001 DATA PRESENTATIONS AT AASLD CONFERENCE
Lyon, France. October 17, 2019 – ENYO Pharma will be present at the AASLD in Boston in November to present four Posters and one Oral presentation For its Lead Compound EYP001. ENYO will also hold KOL Symposium to Provide Scientific Update on Potential Benefits of FXR Agonists for HBV treatment, on the 10th of November.
ENYO PHARMA ANNOUNCES MOVE TO NEW CORPORATE HEADQUARTERS
Lyon, France., October 3rd, 2019 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company’s headquarters to the 8th Arrondissement in Lyon in the BIOSERRA buildings at 60 avenue Rockefeller, to support long-term growth and advancement of pipeline.
ENYO PHARMA ANNOUNCES NEW CFO AND PROVIDES CLINICAL PIPELINE UPDATE
Lyon, France, September 19th, 2019 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced the appointment of Jonathan Lieber as Chief Financial Officer. ENYO Pharma also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company’s FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH).
ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV
Lyon, November 06, 2018 – ENYO Pharma, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of its FXR agonist compound EYP001 in patients with chronic hepatitis B virus infection (CHBV). The company highlights that EYP001 was well-tolerated by patients and induced a prolonged FXR target engagement after QD dosing over 4 weeks. ENYO Pharma will now initiate two Phase II clinical trials of EYP001 in NASH and CHBV.
